Cargando…

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions

OBJECTIVE: To determine the transfer of rituximab, an anti-CD20 monoclonal antibody widely used for neurologic conditions, into mature breast milk. METHODS: Breast milk samples were collected from 9 women with MS who received rituximab 500 or 1,000 mg intravenous once or twice while breastfeeding fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krysko, Kristen M., LaHue, Sara C., Anderson, Annika, Rutatangwa, Alice, Rowles, William, Schubert, Ryan D., Marcus, Jacqueline, Riley, Claire S., Bevan, Carolyn, Hale, Thomas W., Bove, Riley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857908/ https://www.ncbi.nlm.nih.gov/pubmed/31719115 http://dx.doi.org/10.1212/NXI.0000000000000637

Ejemplares similares

Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases
por: LaHue, Sara C., et al.
Publicado: (2020)

Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions
por: Anderson, Annika, et al.
Publicado: (2023)

Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS
por: Anderson, Annika, et al.
Publicado: (2021)

Treatment of Women with Multiple Sclerosis Planning Pregnancy
por: Krysko, Kristen M., et al.
Publicado: (2021)

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD
por: Das, Gitanjali, et al.
Publicado: (2018)

Remote Assessments of Hand Function in Neurological Disorders: Systematic Review
por: Gopal, Arpita, et al.
Publicado: (2022)

Assessing Cognitive Function in Multiple Sclerosis With Digital Tools: Observational Study
por: Hsu, Wan-Yu, et al.
Publicado: (2021)

Well-being at midlife: Correlates of mental health in ambulatory menopausal women with multiple sclerosis
por: Morales-Rodriguez, Denisse, et al.
Publicado: (2023)

CoachMS, an innovative closed-loop, interdisciplinary platform to monitor and proactively treat MS symptoms: A pilot study
por: Block, Valerie J, et al.
Publicado: (2021)

Application of an Adaptive, Digital, Game-Based Approach for Cognitive Assessment in Multiple Sclerosis: Observational Study
por: Hsu, Wan-Yu, et al.
Publicado: (2021)

Correction: Application of an Adaptive, Digital, Game-Based Approach for Cognitive Assessment in Multiple Sclerosis: Observational Study
por: Hsu, Wan-Yu, et al.
Publicado: (2021)

High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics
por: Lui, Allysa, et al.
Publicado: (2021)

Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditions
por: Bove, Riley, et al.
Publicado: (2018)

Development and characterization of an anti-rituximab monoclonal antibody panel
por: Tada, Minoru, et al.
Publicado: (2018)

Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic
por: McGinley, Marisa P, et al.
Publicado: (2021)

Effects of melatonin on sleep disturbances in multiple sclerosis: A randomized, controlled pilot study
por: Hsu, Wan-Yu, et al.
Publicado: (2021)

Minimization of administration route errors with subcutaneous rituximab
por: Liptrott, Sarah, et al.
Publicado: (2016)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology
por: Khandelwal, Krishna, et al.
Publicado: (2023)

Why monkeys do not get multiple sclerosis (spontaneously): An evolutionary approach
por: Bove, Riley M
Publicado: (2018)

The efficacy of rituximab in adult frequently relapsing minimal change disease
por: King, Catherine, et al.
Publicado: (2017)

Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease
por: Guan, Nan, et al.
Publicado: (2023)

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
por: Pierpont, Timothy M., et al.
Publicado: (2018)

The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance
por: Castillo, Jorge J., et al.
Publicado: (2021)

Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies
por: Madanchi, Nima, et al.
Publicado: (2017)

Efficacy of rituximab in thymoma associated minimal change disease: case report
por: El Ouafi, Zhour, et al.
Publicado: (2021)

Efficacy of low-dose rituximab in minimal change disease and prevention of relapse
por: Zhang, Jian, et al.
Publicado: (2023)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022)

The One-Two Punch of Delirium and Dementia During the COVID-19 Pandemic and Beyond
por: LaHue, Sara C., et al.
Publicado: (2020)

Reexamining cholinesterase inhibitors for the prevention and treatment of delirium in high-risk populations
por: Lieberman, Ori J., et al.
Publicado: (2023)

Transitioning From S1P Receptor Modulators to B Cell–Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data
por: Rowles, William M., et al.
Publicado: (2022)

Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?
por: Steiner, Normann, et al.
Publicado: (2016)

From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance
por: Visentin, Andrea, et al.
Publicado: (2022)

Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab
por: Merhi, Basma, et al.
Publicado: (2017)

Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation
por: Ku, Terrance J.Y., et al.
Publicado: (2020)

Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab
por: Rabascall, Carlos X, et al.
Publicado: (2021)

Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease
por: Papakrivopoulou, Eugenia, et al.
Publicado: (2016)

Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
por: Ren, Hong, et al.
Publicado: (2017)

Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?
por: Kannan, Lakshmi
Publicado: (2022)

Use of B-Cell–Depleting Therapy in Women of Childbearing Potential With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
por: Galati, Alexandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p9d6m7n9oavlg83ffoc8gtou7n